Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Delta plus variant identified in UK

What is the “delta plus” variant?

It’s a relative of the delta variant, identified by British scientists last month.

Because it isn’t a variant of interest or concern, it has not yet been officially named after a letter of the Greek alphabet, like the other worrisome variants.

Scientists are monitoring the delta-related variant — known as AY.4.2. — to see if it might spread more easily or be more deadly than previous versions of the coronavirus. In a recent report, U.K. officials said this variant makes up 6% of all analyzed COVID-19 cases in the country and is “on an increasing trajectory.”

The variant has two mutations in the spike protein, which helps the coronavirus invade the body’s cells. These changes have also been seen in other versions of the virus since the pandemic started, but haven’t gone very far, Francois Balloux, director of the Genetics Institute at University College London.

The delta variant remains “by far the most dominant variant in terms of global circulation” said Maria Van Kerkhove, the World Health Organization’s technical lead on COVID-19, at a public session this week.

“Delta is dominant, but delta is evolving,” she said, adding that the more the virus circulates, the greater chances it has to mutate.

Source: Modern Healthcare

https://www.modernhealthcare.com/safety-quality/what-delta-plus-variant-coronavirus

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!